Click on the links above to learn more about upcoming Cytonome seminars and webinars, plus industry conferences and trade shows where you can hear more about high-speed, sterile cell sorting instrumentation for your research and clinical applications.
October 11, 2017
Cytonome Concludes Exclusive Sales Partnership Agreement with Inabata
Cytonome/ST, LLC and Inabata & Co., Ltd. and have concluded an exclusive sales partnership agreement for Cytonome’s proprietary GigaSort® Technology in Japan.
The GigaSort Platform is an application specific laser-based cell sorter that allows the identification, characterization, and isolation of highly purified cell populations. Due to its low pressure parallel microfluidic channel design, the GMP compliant GigaSort Platform provides high throughput processing while remaining gentle on cells. A fully enclosed, single use, fluidic set that contains a microfluidic chip solves the safety and contamination problems that have plagued therapeutic cell sorting applications using conventional aerosol-based cell sorting technologies, thus making the GigaSort Platform a strong candidate solution for high performance cell therapy applications such as regenerative medicine using iPS cells and CAR-T therapy.
About Cytonome/ST, LLC
Headquartered in Bedford, MA, Cytonome/ST, LLC, is a privately held biotechnology instrument company. Cytonome develops advanced solutions in cell purification for the cell therapy, industrial and life science research markets. With deep engineering expertise in the cytometry field and a strong intellectual property portfolio, Cytonome aims to develop products that simplify existing workflows and enable leading edge research and therapies. For more information please visit www.cytonome.com.
Please check with the local and national authorities for any license, approval or clearance requirements in using GigaSort™ technologies for the development of commercial therapies. In the USA, the GigaSort™ system is for Research Use Only. Not for use in Diagnostic or Therapeutic procedures without appropriate FDA approvals.
Cytonome Media Contact:
Katy McGirr, Ph.D.
Director of Marketing and Applications